Search

Cannabidial – Stay Tuned

@LaughinPaulRyan | Wall Street Journal, Main Street and High Times

Tag

marvin washington

Kannalife And Medical Marijuana Inc. Join Forces

NEW YORK, Dec. 22, 2015 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to announce to shareholders and the public a joint effort with investment portfolio company Kannalife Sciences, Inc. (“Kannalife”) to open an opportunity for the public to “show their green” and participate in a fundraiser for research driven by Kannalife at Temple University for the potential use of cannabidiol as a treatment for chronic traumatic encephalopathy (CTE). CTE is the deadly concussion-related disease plaguing a high percentage of current and retired NFL football players and athletes participating in concussion-related sports.
As part of the fundraising initiative, Medical Marijuana, Inc. and Kannalife have co-sponsored and launched the “Show Your Green” public service announcement (PSA) to create awareness of CTE. Executives from both companies also explained to radio listeners on the U-T Community Spotlight radio show how to make a difference through medical research by visiting http://www.treatCTE.org.
At http://www.treatCTE.org, interested donors can “Show Your Green” by sharing photos along with the PSA video with their social networks. All funds committed will go directly into the CTE research being conducted by Kannalife at Temple University.
What is CTE?

Chronic traumatic encephalopathy is a life-threatening and debilitating disease and each football fan now has the opportunity to support awareness of CTE and make a move toward developing a treatment for the concussive injury. CTE is an oxidative stress (OS) related disease. Neural cells suffer functional or sensory loss in neurodegenerative diseases. Apart from several other environmental or genetic factors, oxidative stress leading to free radical attack on neural cells contributes a calamitous role in neurodegeneration.

Leading the “Show Your Green” PSA at http://www.treatCTE.org is Kannalife’s advisory board member and former NFL star defensive lineman, Marvin Washington. Washington now leads Kannalife’s efforts to expand on raising awareness for the disease and the need for a community-driven effort to support the research and development of therapeutic treatments to fight CTE. Speaking out on CTE and the NFL concussion lawsuit, Washington is calling on the public to “follow the signs” and “follow the science” in interviews including: ESPN’s Outside the Lines, NowThis, MSNBC, and Fox News Sports Court.

From 1988 to 1999, Washington played in 155 games over 11 seasons in the NFL, recording over 40 sacks in his eight years with the New York Jets, two years with the San Francisco 49’ers and as a member of the 1998 Superbowl champion Denver Broncos. Having been diagnosed with three known concussions and a countless number of subconcussions, the former NFL star is extremely passionate about helping individuals who are battling the debilitating and often deadly effects of CTE.

At http://www.treatCTE.org, Washington narrates the first of a short series of “Show Your Green” public awareness campaign videos, as he shares facts about CTE including:
When a football player takes a hit, the impact to the brain is 98 times the force of gravity

A recent study shows that 96% of former NFL players tested positive for CTE

CTE has been linked to dementia, depression and suicide; and

There is currently no effective treatment for CTE
Who is researching CTE?

Kannalife Sciences, Inc. (“Kannalife”), an MJNA portfolio company, is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife currently holds two licenses with the National Institutes of Health for U.S. Patent 6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants.” These licenses are currently in use by Kannalife to develop novel therapeutic drugs to treat chronic traumatic encephalopathy (CTE) and hepatic encephalopathy (HE): http://www.google.com/patents/US6630507. Kannalife’s scientific team has researched the effects of cannabidiol (CBD) on non-differentiated native neuronal cells and has determined cannabidiol’s potential as a target drug candidate to treat oxidative stress-related disorders, CBD’s therapeutic index, and CBD’s limitations in pharmaceutical target drug design.
In tandem with its findings on CBD, Kannalife has developed a new cannabidiol-like molecule called KLS-13019 that, through pre-clinical testing and pharmacokinetic (PK) studies, indicates improvement over CBD’s role as a neuroprotectant through increased potency, as well as potential for greater safety through reduced toxicity. Side-by-side comparisons between CBD and KLS-13019 have also shown that KLS-13019 has marked improvements over CBD in oral bioavailability, CNS penetration, blood-plasma concentrations, and cognitive improvement in murine behavioral models.
How can you help?

You can “Show Your Green” and assist in raising awareness in the fight for a cure for CTE though medical research, by going to http://www.treatCTE.org for details.

The Significance of the ‘507 Patent

FACT: The National Institutes of Health has a patent on the therapeutic uses of CBD. 

In 1998, a group of scientists on behalf of the National Institutes of Health filed a patent with the US Patent Office that stated that cannabinoids have medical value.

Co-authored by Nobel Laureate Julius Axelrod, Patent #6,630,507 was awarded to the National Institutes of Health in 2003, just five years after it was filed. This patent is titled, “Cannabinoids as antioxidants and neuroprotectants.”

FACT: The NIH acknowledges the therapeutic properties and potential uses of CBD. 

Colloquially called “the ‘507 patent,” this document describes the potential therapeutic values of non-psychoactive cannabinoids. It describes cannabidiol (CBD) in particular as being a potent antioxidant – stronger than either vitamin C and vitamin E. CBD is also described as having neuroprotective properties, meaning the NIH believes it may protect the brain and nervous system from damage due to head trauma like concussions or brain damage from strokes.

The patent also describes CBD as being very non-toxic, with no possibility of fatal overdose and no damage demonstrated “large, acute doses” of 700mg CBD/day (which is hundreds of times more CBD than most people would ever ingest).

FACT: This patent flies in the face of the Schedule I status of cannabis, which defines cannabis as having “no medical value.”

The US government doesn’t officially recognize the medical potential of marijuana, at least in part because the studies about its potential therapeutic benefits have been small, and there have been no large-scale clinical trials on the plant. However, certain components of marijuana have been made into pharmaceutical drugs for decades like Marinol, which is a synthetic version of THC to treat chemotherapy symptoms.

FACT: The ‘507 patent also means anyone wanting to develop a pharmaceutical drug using CBD would have to receive a license from the NIH to do so.

Fortunately, we have that covered. Medical Marijuana Inc.’s joint venture with KannaLife Sciences includes exclusive and non-exclusive license agreements with the NIH to develop CBD into viable medicines. This is yet another way that we are working towards a future in which cannabinoids are viewed as the true therapeutic powerhouses emerging research indicates they are.

FACT: Contrary to popular belief, this patent isn’t for medical marijuana.

The ‘507 patent covers the potential medical use of non-psychotropic compounds in cannabis, particularly CBD. The ‘507 patent specifically avoids psychotropic cannabinoids (like THC). 

FACT: The ‘507 Patent is among the strongest cases for our CBD business model.

Legitimacy is everything in this world. Operating with the knowledge that one of the most venerable institutions in the world has cataloged the many potential benefits of CBD motivates every business decision we make.

Source: Medical Marijuana Inc.

Blog at WordPress.com.

Up ↑